Search Results 151-160 of 16088 for hla genotype

  1. PREemptive Pharmacogenomic testing for prevention of Adverse drug REactions - Mayo Clinic

    ... genotype associated ADRs which are causally related to the initial drug of inclusion (referred to as 'index drug'). Participation eligibility. Participant ...

  2. A Multiple Dose Study to Evaluate Safety, Tolerability, PK, and Efficacy of SER-155 in Adults Undergoing HSCT - Mayo Clinic

    donor, or HLA 1-antigen mismatched unrelated donor, with either bone marrow or peripheral blood stem cells as a graft source, and with any conditioning ...

  3. Bone marrow transplant - Mayo Clinic

    Plerixafor alone for the mobilization and transplantation of HLA-matched sibling donor hematopoietic stem cells. Blood Advances. 2019; doi:10.1182 ...

  4. Overview - Sudden Death Genomics: Michael J. Ackerman - Mayo Clinic Research

    ... genotype-phenotype relationships. Located in Rochester, Minnesota, and led by principal investigator Michael J. Ackerman, M.D., Ph.D., the Sudden Death ...

  5. Pharmacogenomics: Your Own Prescription Richard Weinshilboum, M.D. Professor, Molecular Pharmacology and Experimental Therapeuti

    have the ability to do very high-quality genotyping, that is, these markers across the genome so we can find genes. And just here at Mayo we have four ...

  6. Copy Number Variation (CNV) Atlas of Human Development - Mayo Clinic

    ... genotype and phenotype information collected during routine clinical care. We will also utilize the database to improve reporting of clinical test results ...

  7. Cardiovascular Tissue Engineering Research Laboratory - Focus Areas

    Griffiths' lab team has developed novel technologies for high-throughput immunoproteomic identification of HLA , non- HLA and nonprotein (for example ...

  8. A Study to Evaluate AFPᶜ³³²T in Advanced HCC - Mayo Clinic

    The Sponsor will review the results of HLA typing for inclusion alleles, and will adjudicate subject eligibility based on HLA results. ... Positive for any HLA-A* ...

  9. Phase 1 Study to Evaluate the Safety of ATA188 in Subjects With Progressive and Relapsing-Remitting Multiple Sclerosis - Mayo Clinic

    In 20 HLA-A2 healthy subjects and 20 HLA-A2 patients we also analysed CD8 T cells specific for individual peptides, measured by binding to HLA-peptide ...

  10. Allogeneic Transplant in HIV Patients (BMT CTN 0903) - Mayo Clinic

    Donor/recipient HLA matching: Related donor ... Unrelated donor: must be a 7/8 or 8/8 match at HLA ... genotype). The results should be included as part ...